Diabetic Retinopathy (DR) is a complication of diabetes that affects the eyes. It is caused by blood vessel damage of the light-sensitive tissue at the back of the retina. Neovascularization are emerged and the small blood vessels are blocked. The prevention or delaying vision loss can be obtained by DR early detection. The retinal microvascular network as a biological system has its own multifractal features as generalized dimensions, lacunarity and singularity spectrum. In this study, a novel approach for DR early detection based on the multifractal geometry has been proposed in some details. Analyzing the macular optical coherence tomography angiography (OCTA) images for diagnosing early non-proliferative diabetic retinopathy (NPDR). Using a supervised machine learning method as a Support Vector Machine (SVM) algorithm to automate the diagnosis process and improving the resultant accuracy. The classification technique had achieved 98.5 % accuracy. This approach also can classify easily other diabetic retinopathy stages or other retinal diseases, which affect the vessels or neovascularization distribution.
Alzheimer's Disease (AD) is considered one of the most diseases that much prevalent among elderly people all over the world. AD is an incurable neurodegenerative disease affecting cognitive functions and were characterized by progressive and collective functions deteriorating. Remarkably, early detection of AD is essential for the development of new and invented treatment strategies. As Dementia causes irreversible damage to the brain neurons and leads to changes in its structure that can be described adequately within the framework of multifractals. Hence, the present work focus on developing a promising and efficient computing technique to pre-process and classify the AD disease especially in the early stages using multifractal geometry to extract the most changeable features due to AD. Then, A machine learning classification algorithm (K-Nearest Neighbor) has been implemented in order to classify and detect the main four early stages of AD. Two datasets have been used to ensure the validation of the proposed methodology. The proposed technique has achieved 99.4% accuracy and 100% sensitivity. The comparative results show that the proposed classification technique outperforms is recent techniques in terms of performance measures.
Acute Lymphoblastic Leukemia (ALL) is a cancer that infects the blood cells causing the development of lymphocytes in large numbers. Diagnostic tests are costly and very time-consuming. It is important to diagnose ALL using Peripheral Blood Smear (PBS) images, especially in the initial screening cases. Several issues affect the examination process such as diagnostic error, symptoms, and nonspecific nature signs of ALL. Therefore, the objective of this study is to enforce machine-learning classifiers in the detection of Acute Lymphoblastic Leukemia as benign or malignant after using the grey wolf optimization algorithm in feature selection. The images have been enhanced by using an adaptive threshold to improve the contrast and remove errors. The model is based on grey wolf optimization technology which has been developed for feature reduction. Finally, acute lymphoblastic leukemia has been classified into benign and malignant using K-nearest neighbors (KNN), support vector machine (SVM), naïve Bayes (NB), and random forest (RF) classifiers. The best accuracy, sensitivity, and specificity of this model were 99.69%, 99.5%, and 99%, respectively, after using the grey wolf optimization algorithm in feature selection. To ensure the effectiveness of the proposed model, comparative results with other classification techniques have been included.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.